Beigene, Ltd. (NASDAQ:ONC – Get Free Report) COO Xiaobin Wu sold 21,267 shares of the company’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $240.07, for a total transaction of $5,105,568.69. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Xiaobin Wu also recently made the following trade(s):
- On Tuesday, February 18th, Xiaobin Wu sold 30,654 shares of Beigene stock. The shares were sold at an average price of $240.74, for a total transaction of $7,379,643.96.
Beigene Stock Performance
ONC opened at $244.20 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. Beigene, Ltd. has a twelve month low of $126.97 and a twelve month high of $248.16. The stock has a market cap of $23.90 billion, a P/E ratio of -29.64, a P/E/G ratio of 9.50 and a beta of 0.63.
Beigene Company Profile
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Further Reading
- Five stocks we like better than Beigene
- Options Trading – Understanding Strike Price
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- Are Penny Stocks a Good Fit for Your Portfolio?
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.
